buquineran (BDPU)

cardiac stimulant; structure

Also Known As:

BDPU; 1-butyl-3-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)urea; UK 14,275; UK 14275; UK-14275; urea, N-butyl-N'-(1-(6,7-dimethoxy-4-quinazolinyl)-4-piperidinyl)-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - buquineran: 2

Related Diseases

1.	Coronary Artery Disease (Coronary Atherosclerosis) 01/01/1978 - "Some aspects of the cardiovascular pharmacology of UK 14,275 in patients with coronary artery disease." 01/01/1978 - "1. A phosphodiesterase inhibitor, UK 14,275 (Pfizer) was administered intravenously to six patients with suspected coronary artery disease under-going diagnostic cardiac catheterisation to assess its inotropic activity. "
2.	Bradycardia 09/01/1987 - "With the exception of buquineran and carbazeran, which produced bradycardia and were therefore force specific, all of the recently discovered PDE inhibitors increased the rate of contraction of the right atria and they were rate selective to the same extent as IBMX, isoprenaline and forskolin. "

Related Drugs and Biologics

1.	1-Methyl-3-isobutylxanthine (1 Methyl 3 isobutylxanthine)
2.	Phosphodiesterase Inhibitors
3.	Isoproterenol (Isoprenaline)
4.	Colforsin
5.	carbazeran